Want to join the conversation?
$BAX, which develops products that treat hemophilia, kidney disease immune disorders, said it expects 3Q16 adjusted EPS from continuing operations of $0.43-0.45. The company expects sales growth of 2-3% on reported basis and 3-4% on constant currency basis. $BAX anticipates GAAP EPS of $0.25-0.29.
Looking forward to the first $TSLA earnings after SolarCity acquisition.
What will be an ideal EPS range for $PZZA in its earnings today?